Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | MAPT | P10636 | 3/20 | 0.97 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | CTSB | P07858 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14726057 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNAMAPTKCNJ1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16370438 | 0.98 | ALDH1A1 (0.94) | ALDH1A1LMNAMAPTKCNJ1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29388956 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNAMAPTKCNJ1SMN1; SMN2 | |
| SCHEMBL1648931 | 0.93 | LMNA (0.83) | ALDH1A1LMNAMAPTKCNJ1SMN1; SMN2 | |
| SCHEMBL15832718 | 0.91 | ALDH1A1 (0.86) | ALDH1A1LMNAMAPTKCNJ1SMN1; SMN2 | |
| SCHEMBL17268269 | 0.88 | ALDH1A1 (0.80) | ALDH1A1LMNAMAPTKCNJ1SMN1; SMN2 | |
| SCHEMBL3156886 | 0.84 | KDM4E (0.73) | ALDH1A1LMNAMAPTKCNJ1SMN1; SMN2 | |
| SCHEMBL2206628 | 0.84 | KDM4E (0.73) | ALDH1A1LMNAMAPTKCNJ1SMN1; SMN2 | |
| SCHEMBL852960 | 0.84 | KCNJ1 (0.79) | ALDH1A1LMNAMAPTKCNJ1SMN1; SMN2 | |
| SCHEMBL19419599 | 0.83 | ALDH1A1 (0.69) | ALDH1A1LMNAMAPTKCNJ1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111403607-A | Chelated perovskite material, film, device and preparation method and application thereof | 华东理工大学 | 2020-07-10 | — | — | CN | claimed |
| US-20250243154-A1 | CRYSTALLINE 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE DI-HYDROCHLORIDE DI-HYDRATE | GEN1E LIFESCIENCES INC. | 2025-07-31 | — | — | US | disclosed |
| US-12269792-B2 | Crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl) phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate | GENIE LIFESCIENCES INC. (US) | 2025-04-08 | — | — | US | disclosed |
| CN-115215816-B | Synthesis method of lactam compound | 普济生物科技（台州）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023237759-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR | ANAGENESIS BIOTECHNOLOGIES (FR) | 2023-12-14 | — | — | WO | disclosed |
| EP-4289427-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR. | Anagenesis Biotechnologies (FR) | 2023-12-13 | — | — | EP | disclosed |
| CN-111566100-B | Pyrimidine compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-4237415-A1 | CRYSTALLINE 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL) NAPHTHALENE-1-SULFONAMIDE DI-HYDROCHLORIDE DI-HYDRATE | GEN1E Lifesciences Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116367838-A | Crystalline 5- (dimethylamino) -N- (4- (morpholinomethyl) phenyl) naphthalene-1-sulfonamide dihydrochloride dihydrate | GEN1E生命科学公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-115215816-A | Synthesis method of lactam compound | 普济生物科技（台州）有限公司 | 2022-10-21 | — | — | CN | disclosed |
| WO-1999032100-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032468-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| US-5861402-A | BRADYKININ ANTAGONISTS USEFUL FOR THE TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, COMMON COLD, ALLERGIES, ASTHMA, PANCREATITIS, BURNS, VIRUS INFECTION, HEAD INJURY, MULTIPLE TRAUMA | PFIZER PHARMACEUTICALS, INC. (JP) | 1999-01-19 | — | — | US | disclosed |
| US-5807885-A | Amidine derivatives with nitric oxide synthetase activities | ASTRA AKTIEBOLAG (SE) | 1998-09-15 | — | — | US | disclosed |
| EP-0790239-A1 | Novel 4-phenyl-2-(piperazinyl/perhydrodiazepinyl/aminoalkyl)carbonylmethyl)-1,4-dihydropyridine-3,5-dicarboxylic acid derivatives as bradykinin receptor antagonists | PFIZER INC. (US) | 1997-08-20 | — | — | EP | disclosed |
| CN-1132505-A | Amidine derivatives with nitric oxide synthetase activities | ASTERA CO (SE) | 1996-10-02 | — | — | CN | disclosed |
| US-5556969-A | Benzodiazepine derivatives | MERCK SHARP & DOHME LTD. (GB) | 1996-09-17 | — | — | US | disclosed |
| EP-0713483-A1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | Astra Aktiebolag (SE) | 1996-05-29 | — | — | EP | disclosed |
| WO-1996002510-A1 | NOVEL 1-[4(AMINO METHYL)PHENYL] SUBSTITUTED QUINOLONE CARBOXYLIC ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-02-01 | — | — | WO | disclosed |
| WO-1995005363-A1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | ASTRA AKTIEBOLAG (SE) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12269792-B2 | Crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl) phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate | REN, PKD1, DSP | ALDH1A1 1921/4885LMNA 595/4885MAPT 385/4885 |
| US-20250243154-A1 | CRYSTALLINE 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE DI-HYDROCHLORIDE DI-HYDRATE | REN, PKD1, DSP | ALDH1A1 1921/4885LMNA 595/4885MAPT 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.